Redeye comments on GiG’s Q2-results which came in above expectations driven by strong profitability ...
Raute reports Q2 results on Aug 25. We see Q2 a bit soft but growth is set to continue next year wit...
Taaleri reported Q2 EBIT of EUR 17.8m, coming clearly above Refinitiv consensus at EUR 8.
Netcompany has today released its Q2 2023 interim report, which at first glance looks slightly disap...
Redeye retains its positive view despite lowering its forecasts and Base Case.
Redeye is encouraged to see a stabilisation in Sleep Cycle’s total number of subscribers, thanks to ...
Redeye updates on EG7 post its Q2-results which came in close to our expectations.
Arcede Pharma räknar med att slutföra den sista toxikologistudien i augusti 2023 och har aviserat om...
Redeye lowers its sales estimates on all time horizons for Sedana Medical following the Q2 report, r...
Fortsatt leverans från bolaget Omsättningen i kvartalet uppgick till 30,2 mkr, vilket motsvarar en t...
Redye comments on Alelion’s Q2 report, which was largely in line with our expectations.
Redeye comments on Physitracks’s Q2-results, wherein the reported figures generally align with our e...
Sales SEK 17.9m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -0.
Redeye retains its positive view of Hexatronic following a solid Q2 2023 but with soft guidance for ...
Redeye comments on EG7’s Q2-results which was in line with expectations where performance in the Gam...
En optimerad försäljningsmix resulterade i en rekordhög nettovinst för kvartalet och vi prognostiser...
We cut '24e-'25e sales by 32-8% due to the Ovzon-3 delay We now expect Ovzon-3 to generate sales as ...
Q2: EBITDA PLN 69m vs. ABGSCe of PLN 112m Paper market balance under pressure from weak demand Fair ...
Redeye updates its fair value range following FlexQube’s share issue announcement, where it aims to ...
Redeye reiterates its fair value range following a solid Q2’23 report that presented surprisingly so...
